Table 6.
No. of Isolates AST Reference a |
No. of Isolates MICPFAST1 b | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Antimicrobial | Total | R | I | S | R | I | S | CA c (no. [%]) |
mE d (no. [%]) |
ME e (no. [%]) |
VME f (no. [%]) |
Penicillin | 87 | 10 | 9 | 68 | 12 | 8 | 67 | 84 (97) | 2 (2) | 1 (1) | 0 (0) |
Meropenem g | 53 | 0 | 0 | 53 | 1 | 0 | 52 | 52 (98) | 0 (0) | 1 (2) | 0 (0) |
Ceftriaxone f | - | - | - | - | - | - | - | - | - | - | - |
Ampicillin g | 53 | 12 | 6 | 35 | 14 | 2 | 37 | 49 (92) | 4 (8) | 0 (0) | 0 (0) |
Levofloxacin h | 63 | 1 | 0 | 62 | 1 | 0 | 62 | 63 (100) | 0 (0) | 0 (0) | 0 (0) |
Vancomycin | 87 | 2 | 0 | 85 | 1 | 0 | 86 | 86 (99) | 0 (0) | 0 (0) | 1 (1) |
Clindamycin | 87 | 16 | 0 | 71 | 16 | 0 | 71 | 85 (98) | 0 (0) | 1 (1) | 1 (1) |
Trimethoprim/Sulfamethoxazole | 87 | 4 | 0 | 83 | 4 | 0 | 83 | 85 (98) | 0 (0) | 1 (1) | 1 (1) |
Chloramphenicol | 87 | 3 | 0 | 84 | 2 | 0 | 85 | 86 (99) | 0 (0) | 0 (0) | 1 (1) |
Linezolid i | 63 | 0 | 0 | 63 | 0 | 0 | 63 | 63 (100) | 0 (0) | 0 (0) | 0 (0) |
a Number of isolates tested with the reference method and classified as R resistant; I, susceptible, increased exposure; S, susceptible; b number of isolates tested with the evaluated method and classified as R resistant; I, susceptible, increased exposure; S, susceptible; c CA, categorical agreement; d mE, minor error; e ME, major error; f VME, very major error; g The susceptibility of streptococcus group A, B, C, G to cephalosporins is inferred from the benzylpenicillin susceptibility, no breakpoint available on disc diffusion; h Only interpretation for S. pneumoniae and S. viridans group; i Only interpretation for S. pneumoniae, S. viridans group, and S. anginosus group.